Compare Abercrombie & Fitch Co. (ANF) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs Viatris Inc — how do they compare? Abercrombie & Fitch Co. trades at $119.22 (market cap $5.24B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 3.6× Abercrombie & Fitch Co.'s market cap, and Viatris Inc pays a 2.95% dividend while Abercrombie & Fitch Co. pays none. Which is the better fit depends on your goals.
| ANF | VTRS | |
|---|---|---|
Market Cap | $5.24B | $18.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $17.86 |
52-Week Low | $65.61 | $9.49 |
Enterprise Value | $5.91B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANF trades at $118.53, up 5.25% today, reflecting strong momentum. The stock exhibits bullish technical signals with support at $114 and resistance at $121. Fundamentally, the company reported robust earnings, with Q1 2026 EPS of $1.47 beating expectations of $1.28, and revenue growth from $4.3B in 2024 to $4.95B in 2025. Profitability metrics are solid, with a net income margin of 11.44% in 2025 and ROE of 39.04%.
Outlook is positive due to consistent earnings beats and strategic campaigns, but risks include market volatility and competitive pressures. Analysts are mixed with a consensus price target of $112.86, below the current price, suggesting potential overvaluation. Institutional interest is growing, with Amundi increasing its stake by 201.2% in Q2 2026.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
